47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

Clinical Definitions & The Premenstrual Spectrum

Premenstrual disorders encompass a spectrum of cyclical physical, affective, and behavioral symptoms that recur specifically during the luteal phase of the ovulatory menstrual cycle and resolve rapidly following the onset of menses. Recognizing this spectrum is essential in primary care to prevent over-diagnosis, avoid inappropriate psychotropic prescribing, and validate genuine, severe functional disability.

The Premenstrual Continuum

1. Premenstrual Symptoms (Physiologic Premenstrual Changes):
   • Experienced by up to 80% to 85% of ovulating women.
   • Mild, manageable physiological changes such as transient abdominal bloating, mild breast tenderness (mastalgia), mild fatigue, and specific food cravings (e.g., carbohydrates, chocolate).
   • These symptoms do not cause significant subjective distress, do not impair social or occupational functioning, and do not constitute a medical disorder.
2. Premenstrual Syndrome (PMS):
   • Affects approximately 20% to 30% of women of reproductive age.
   • Characterized by at least one moderate physical symptom (bloating, breast swelling, headache) and at least one affective symptom (irritability, mood swings, anxiety) occurring regularly during the 5 to 7 days preceding menses.
   • Symptoms cause moderate subjective distress and modest social or interpersonal interference but do not severely incapacitate daily functioning. Follicular phase is completely symptom-free.
3. Premenstrual Dysphoric Disorder (PMDD):
   • A severe, disabling psychiatric disorder recognized in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5; under Depressive Disorders).
   • Affects 3% to 5% of menstruating females.
   • Dominated by profound affective and psychological destabilization (severe dysphoria, extreme irritability, explosive anger, affective lability, and interpersonal conflict) that causes marked impairment in social, occupational, or academic functioning.

---

Neurobiology & Pathophysiology: The Neurosteroid-GABA Axis

A critical clinical teaching point for board examinations and clinical practice is that PMDD is NOT an endocrine deficiency or hormone imbalance state.

Normal Gonadal Hormone Levels

• Repeated clinical trials have demonstrated that circulating plasma concentrations of estrogen (17-beta estradiol), progesterone, and gonadotropins (LH, FSH) in women with severe PMDD are completely normal and indistinguishable from healthy, asymptomatic controls.
• Women with PMDD do not produce excessive estrogen or inadequate progesterone; rather, they exhibit an abnormal neurobiological vulnerability and heightened central nervous system sensitivity to normal, physiological cyclical fluctuations of gonadal steroids.

                  THE NEUROBIOLOGICAL CASCADE OF PMDD

   1. Normal Ovulation occurs
      └── Corpus luteum synthesizes progesterone during the luteal phase
          └── Progesterone is metabolized across the blood-brain barrier into ALLOPREGNANOLONE

   2. Allopregnanolone & The GABA-A Receptor
      └── Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors
      └── In healthy women: promotes calm, sedation, and anxiolytic tone
      └── In PMDD: altered GABA-A receptor subunit composition (alpha-4, beta-2, delta subunits)
          results in PARADOXICAL CNS EXCITATION, irritability, and anxiety in response to allopregnanolone

   3. Luteal Phase Withdrawal
      └── Late luteal corpus luteum demise causes a precipitous PLUNGE in allopregnanolone levels
      └── Induces acute GABA-ergic withdrawal and central SEROTONERGIC HYPOFUNCTION
      └── Manifests clinically as severe affective lability, emotional outbursts, and dysphoria

The Role of Central Serotonin Transmission

• Estrogen and progesterone heavily modulate central serotonergic (5-HT) neurotransmission by regulating serotonin receptor expression, reuptake transporter density, and turnover.
• Women with PMDD exhibit abnormal central serotonergic responsivity: during the luteal phase, central serotonin levels fall precipitously. This serotonin deficit mediates depressive mood, carbohydrate cravings, pain hypersensitivity, and loss of impulse control.
• This direct biological link explains why Selective Serotonin Reuptake Inhibitors (SSRIs) provide immediate therapeutic efficacy.

---

DSM-5 Diagnostic Criteria for PMDD

To establish a formal diagnosis of PMDD under DSM-5 criteria, all of the following criteria (A through E) must be satisfied.

Criterion A: Symptom Timing & Requirements

In the majority of menstrual cycles over the preceding 12 months, at least 5 symptoms must be present in the final week before the onset of menses, start to improve within a few days after the onset of menses, and become minimal or entirely absent in the week post-menses (follicular phase).

The Core Affective Symptoms (Must Have At Least ONE)

At least one of the following four core emotional symptoms must be present:

1. Marked affective lability (e.g., sudden tearfulness, mood swings, feeling suddenly overwhelmed, or heightened sensitivity to interpersonal rejection);
2. Marked irritability or anger or increased interpersonal conflicts;
3. Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts;
4. Marked anxiety, tension, and/or feelings of being "keyed up" or on edge.

Additional Symptoms (To Reach a Total of At Least Five)

One or more of the following symptoms must be present to reach the required total of 5 symptoms (when combined with core symptoms above): 5. Decreased interest in usual activities (work, school, hobbies, friends); 6. Subjective difficulty in concentration or mental fog; 7. Lethargy, easy fatigability, or marked lack of energy; 8. Marked change in appetite, overeating, or specific food cravings (particularly sugars/carbohydrates); 9. Hypersomnia or insomnia; 10. A sense of being overwhelmed or out of control; 11. Physical symptoms such as breast tenderness or swelling, joint or muscle pain, sensation of bloating, or weight gain.

Criteria B, C, D, and E

• Criterion B (Functional Impairment): Symptoms are associated with clinically significant distress or interference with work, school, usual social activities, or interpersonal relationships (e.g., marital conflict, avoidance of social gatherings, missed workdays).
• Criterion C (Differential Exclusion): The disturbance is not merely an exacerbation of the symptoms of another psychiatric disorder, such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder, or a personality disorder (although PMDD can co-exist with these disorders).
• Criterion D (The Mandatory Confirmation): Criterion A must be confirmed by prospective daily ratings during at least two consecutive symptomatic menstrual cycles.
• Criterion E (Substance & Medical Exclusion): The symptoms are not attributable to the physiological effects of a substance (substance abuse, medication side effect) or a general medical condition (e.g., hyperthyroidism, hypothyroidism).

---

The Mandatory Diagnostic Requirement: Prospective Daily Symptom Charting

[!CAUTION] CRITICAL CLINICAL MANDATE: NEVER DIAGNOSE PMDD RETROSPECTIVELY A clinician CANNOT definitively diagnose PMDD based solely on a patient's retrospective recall of symptoms during an initial clinic visit.

Studies reveal that up to 50% of women who report "severe PMS/PMDD" on retrospective recall do NOT actually have PMDD when tracked prospectively. Instead, many suffer from chronic underlying Major Depressive Disorder, Generalized Anxiety Disorder, or dysthymia with Premenstrual Exacerbation (PME). Initiating targeted PMDD therapy without prospective confirmation risks mismanaging underlying psychiatric disease.

Validated Prospective Tracking Instruments

• Daily Record of Severity of Problems (DRSP): The gold-standard validated instrument. The patient rates the severity of 21 emotional and physical items on a daily Likert scale (1 = not at all, to 6 = extreme) every evening for at least two consecutive menstrual cycles.
• Visual Analogue Scales (VAS) or Menstrual Symptom Calendars: Acceptable alternatives.

                  PROSPECTIVE DAILY LOGGING: PMDD vs. PME vs. CHRONIC MDD

   Menstrual Phase          PMDD Trajectory             Premenstrual Exacerbation   Chronic Major Depression
                            (True Disorder)             (PME of MDD or GAD)         (No Cycle Link)
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════
   Follicular Phase         COMPLETELY ASYMPTOMATIC     Mild to Moderate Baseline   Continuous, unremitting
   (Cycle Days 4 to 10)     (Score: 1 / None)           Depression or Anxiety       Severe Depression
   
   Ovulation (Day 14)       Symptom-free                Mild Baseline Symptoms      Continuous Depression
   
   Late Luteal Phase        EXPLOSIVE SYMPTOM ONSET     SEVERE SPIKE in symptoms    Moderate to Severe
   (Days -7 to -1)          (Score: 5-6 / Severe)       above chronic baseline      Depression unchanged
   
   Menses Onset             RAPID COMPLETE RESOLUTION   Worsening remits to         Persistent Depression
   (Days +1 to +3)          within 48 to 72 hours       baseline chronic symptoms   continues throughout
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════

Clinical Interpretation of the DRSP

• True PMDD: Confirmed when daily charting demonstrates a >=30% increase in symptom severity during the 7 days prior to menses compared with the postmenstrual baseline (Cycle Days 4 to 10), accompanied by a completely symptom-free interval (follicular remission).
• Premenstrual Exacerbation (PME): Diagnosed when symptoms worsen during the luteal phase but never resolve completely during the follicular phase. The patient retains persistent, low-to-moderate baseline depressive or anxiety symptoms during Days 4 through 10. Management requires treating the primary underlying major depression or anxiety disorder.

---

Differential Diagnosis & Medical Workup

                  DIFFERENTIAL DIAGNOSIS & TRIAGE FOR PMDD

   Condition                   Distinguishing Clinical Features                Diagnostic Workup
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════
   Major Depressive Disorder   Continuous, chronic depressed mood/anhedonia   PHQ-9; prospective daily log
   / GAD                       persisting throughout follicular phase; no      demonstrates absence of a
                               symptom-free window.                            symptom-free follicular window.
   
   Perimenopausal Transition   Irregular cycle frequency; hot flushes, night   Serum FSH / estradiol (elevated
                               sweats, sleep fragmentation; age >40 to 45.     FSH variable; clinical diagnosis).
   
   Thyroid Dysfunction         Hypothyroidism causes fatigue, weight gain,     Serum TSH (mandatory screening
                               constipation, depression; hyperthyroidism        test in all suspected cases).
                               causes anxiety, palpitations, irritability.     
   
   Substance / Alcohol Use     Symptoms correlate with intoxication or         CAGE / AUDIT-C screening;
   Disorders                   withdrawal; no strict luteal restriction.       targeted urine toxicology.
   
   Dysmenorrhea /              Severe pelvic pain, cramping, dyspareunia;      Pelvic TVUS; pelvic exam;
   Endometriosis               lacks primary affective/psychological lability. dysmenorrhea peaks WITH flow.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════

• Laboratory Evaluation: In every patient presenting with suspected PMS or PMDD, obtain a serum TSH to rule out occult thyroid disease. Additional testing (CBC, comprehensive metabolic panel) is guided by clinical suspicion.

---

First-Line Lifestyle & Behavioral Modifications

For mild premenstrual symptoms or as adjunctive therapy in confirmed PMDD:

• Regular Aerobic Exercise: Engaging in >=150 minutes of moderate-intensity aerobic physical activity per week (e.g., brisk walking, jogging, swimming, cycling) increases central endorphin concentrations, reduces fatigue, improves premenstrual mood, and alleviates perceived abdominal bloating.
• Dietary Modifications:
  • Complex Carbohydrates: Ingesting complex carbohydrates (whole grains, oats, legumes) promotes sustained, steady insulin release, which enhances cerebral tryptophan uptake and facilitates central serotonin synthesis, reducing luteal mood swings.
  • Restrict Sodium: Limiting dietary salt reduces extracellular fluid volume expansion, relieving breast swelling and peripheral edema.
  • Limit Refined Sugars, Caffeine & Alcohol: Caffeine exacerbates premenstrual anxiety, irritability, sleep disturbances, and fibrocystic breast tenderness. Alcohol worsens luteal emotional volatility and destabilizes sleep architecture.
• Sleep Hygiene & Stress Management: Cognitive Behavioral Therapy (CBT) specifically adapted for premenstrual disorders has demonstrated substantial efficacy in reducing depressive cognitions and enhancing coping mechanisms.
• Evidence-Based Nutritional Supplements:
  • Calcium Carbonate (1,200 mg PO daily): Randomized controlled trials show a significant reduction in luteal emotional symptoms, food cravings, and water retention.
  • Pyridoxine (Vitamin B6; 50 to 100 mg PO daily): Cofactor in serotonin and dopamine synthesis. Safety Alert: Do not exceed 100 mg/day due to the established risk of sensory peripheral neuropathy.
  • Magnesium (200 to 400 mg PO daily): Reduces fluid retention, bloating, and menstrual migraines.

---

First-Line Pharmacotherapy: Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs represent the undisputed first-line pharmacotherapy for PMDD, supported by Category A evidence from numerous randomized double-blind placebo-controlled trials and Cochrane systematic reviews.

                  FIRST-LINE SSRI REGIMENS FOR CONFIRMED PMDD

   Medication          Continuous Daily Regimen          Intermittent Luteal-Phase Regimen
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════
   Fluoxetine*         20 mg PO once daily               20 mg PO daily starting on Cycle Day 14
                       (titrate to max 40 mg)            and discontinued at the onset of menses
   
   Sertraline*         50 to 100 mg PO once daily        50 to 100 mg PO daily starting on Cycle Day 14
                       (titrate to max 150 mg)           and discontinued at the onset of menses
   
   Paroxetine CR*      12.5 to 25 mg PO once daily       12.5 to 25 mg PO daily starting on Day 14
                       (controlled-release)              and discontinued at the onset of menses
   
   Escitalopram /      10 to 20 mg PO once daily         10 to 20 mg PO daily starting on Day 14
   Citalopram (off-lab)(titrate to max 20 mg)            and discontinued at the onset of menses
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════
   *Note: Formulations formally approved by the US FDA specifically for the treatment of PMDD.

The Unique Pharmacodynamics of SSRIs in PMDD

[!IMPORTANT] THE CRITICAL BOARD PEARL: RAPID SSRI ONSET IN PMDD A fundamental pharmacologic distinction exists between using SSRIs for Major Depressive Disorder versus PMDD:

1. Major Depressive Disorder: SSRIs require 4 to 6 weeks of continuous daily administration to downregulate somatodendritic 5-HT1A autoreceptors, increase synaptic serotonin, and stimulate hippocampal neurogenesis (BDNF transcription).
2. Premenstrual Dysphoric Disorder: SSRIs produce dramatic, robust symptom relief within 24 to 48 HOURS of administration!

Biological Mechanism: In PMDD, SSRIs do not rely on slow genomic transcription. Instead, SSRIs act via an acute, non-genomic allosteric mechanism that rapidly enhances the activity of the neurosteroid-synthesizing enzyme aldo-keto reductase (AKR1C2 / 5-alpha-reductase). This rapidly normalizes limbic allopregnanolone levels, restoring normal inhibitory GABA-A receptor function within hours.

Intermittent (Luteal-Phase) vs. Continuous SSRI Dosing

Because SSRIs act within 24 to 48 hours in PMDD, clinicians can utilize two distinct dosing paradigms with equivalent clinical efficacy:

1. Intermittent Luteal-Phase Dosing:
   • The patient initiates the SSRI on Cycle Day 14 (or at the estimated time of ovulation) and takes it daily until the onset of menstrual bleeding (or 1-2 days after flow starts), at which point the medication is stopped.
   • The patient takes NO medication during the entire follicular phase (Cycle Days 1 through 13).
   • Major Advantages:
     • Reduces drug exposure by 50% across the patient's lifespan;
     • Substantially reduces medication financial costs;
     • Prevents long-term chronic adverse effects, particularly persistent sexual dysfunction (anorgasmia, decreased libido) and weight gain;
     • Discontinuation syndrome does not occur because of the brief duration of exposure.
   • Best candidates: Women with strictly regular, predictable menstrual cycles (e.g., 28-day cycles) and no baseline mood or anxiety symptoms.
2. Continuous Daily Dosing:
   • The patient takes the SSRI every single day of the month without interruption.
   • Best candidates: Women with irregular or unpredictable menstrual cycle lengths (where predicting Day 14 is impossible), women with co-existing mild baseline dysthymia/anxiety, or women who find starting and stopping medication confusing.
3. Symptom-Onset Dosing:
   • Initiating the SSRI on the very first day premenstrual symptoms manifest and stopping at menses onset. Effective in a subset of highly attuned patients with variable cycle lengths.

---

Second-Line & Hormonal Therapies: Drospirenone & GnRH Agonists

When SSRIs are ineffective, poorly tolerated (due to nausea, insomnia, or severe sexual side effects), or when the patient concurrently desires highly effective contraception, hormonal ovulation suppression is the next step.

Combined Oral Contraceptives Containing Drospirenone

• Mechanism: Combined oral contraceptives (COCs) suppress the hypothalamic-pituitary-ovarian axis by providing negative feedback on pituitary LH and FSH secretion, thereby completely abolishing ovulation and preventing corpus luteum formation. Without a corpus luteum, cyclical progesterone and allopregnanolone surges are extinguished.
• The Molecule: Drospirenone:
  • Drospirenone is a unique synthetic progestin derived from 17-alpha-spironolactone.
  • It possesses potent anti-mineralocorticoid activity (antagonizes aldosterone receptors, directly blocking sodium and water retention) and anti-androgenic activity.
  • Clinical Benefits: Effectively treats somatic water retention, abdominal bloating, cyclic weight gain, and mastalgia, while improving acne and hirsutism.
• The FDA-Approved 24/4 Dosing Regimen:
  • Drospirenone 3 mg / Ethinyl Estradiol 20 mcg in a 24/4 regimen (24 active hormonal tablets followed by only 4 inactive placebo tablets; e.g., Yaz).
  • Why 24/4? Traditional 21/7 COC formulations feature a 7-day hormone-free interval, which allows endogenous follicular recruitment, transient hormone rises, and escape of distressing premenstrual symptoms. Shortening the hormone-free window to 4 days provides profound, stable hormonal suppression and superior PMDD symptom control.
  • Safety Warning: Drospirenone's anti-mineralocorticoid properties can cause mild potassium retention. Serum potassium should be monitored if co-administered with other potassium-sparing agents (ACE inhibitors, ARBs, potassium-sparing diuretics, daily NSAIDs).

Gonadotropin-Releasing Hormone (GnRH) Agonists

• Mechanism: Continuous administration of a GnRH agonist produces initial transient pituitary stimulation followed by profound downregulation and desensitization of GnRH receptors, extinguishing LH and FSH secretion. This induces a state of reversible medical oophorectomy (chemical menopause), completely eliminating cyclical gonadal steroid production.
• Regimen:
  • Leuprolide depot (3.75 mg IM monthly) or Goserelin subcutaneous implant.
  • Mandatory "Add-Back" Therapy: Because profound hypoestrogenism causes rapid bone mineral density loss (osteopenia/osteoporosis) and severe vasomotor symptoms (hot flushes, vaginal atrophy), low-dose add-back hormone therapy is mandatory if treatment extends beyond 3 to 6 months:
    • Continuous low-dose oral 17-beta estradiol (1 mg daily) or transdermal estradiol patch (0.05 mg daily) combined with continuous oral medroxyprogesterone acetate (2.5 mg daily) or micronized progesterone (100 mg daily).
• Indications: Reserved exclusively for severe, incapacitating PMDD that has failed maximized trials of both continuous/intermittent SSRIs and drospirenone-containing COCs.

Bilateral Oophorectomy (Definitive Surgical Extirpation)

• Bilateral Salpingo-Oophorectomy (BSO), typically with concurrent hysterectomy, is a permanent, irreversible procedure of last resort.
• Strict prerequisite: The patient must demonstrate complete, unambiguous symptom remission during a 3- to 6-month trial of GnRH agonist medical suppression to definitively prove that her psychiatric disability is driven by ovarian cyclicity before undergoing irreversible surgical castration.